disclaim financi forecast recommend current review
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim feb
price data apr
rate updat apr
currenc amount express
valuat growth profit
methodolog valu compani
lead drug jakafi initi gain traction drug
approv sever myelofibrosi mf rare blood disord
jakafi monopoli mf market like continu
especi two lead competitor drug left play
field lacklust pivot trial data expand jakafi
label polycythemia vera pv late evalu
drug essenti thrombocythemia et steroid refractori acut
graft versu host diseas agvhd push peak
sale billion
promis rapidli progress inhibitor program
anoth essenti part long-term growth trajectori
partner sever larg pharma firm loath
lose next wave immuno-oncolog innov
lead pack merck combin trial evalu
inhibitor keytruda epacadostat metastat melanoma
howev drug also progress pivot test across
legion indic combin merck keytruda
roch tecentriq
anoth near-term driver jak inhibitor olumi baricitinib
approv europ rheumatoid arthriti earli
partner estim ra
billion-plu market repres compel opportun oral
treatment like olumi could significantli increas
treatment penetr rate grow market oral jak
inhibitor xeljanz first market believ safeti concern
may weigh market penetr leav opportun
olumi cleaner safeti profil take share near
term compani also robust late-stag pipelin focus
primarili oncolog autoimmun indic provid
attract long-term growth opportun firm
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog
drug iclusig chronic myeloid leukemia pipelin includ broad
array oncolog autoimmun program includ ido inhibitor
epacadostat next-gener jak inhibitor itacitinib
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
put fair valu estim
review adjust model recent disappoint
data ido inhibitor epacadostat weve previous
point epacadostat key driver compani
rate particularli see epacadostat data
on-going phase studi base jakafi entrench
posit myeloprolif neoplasm market
inclin leav narrow moat rate place
discuss note last week merck
announc phase studi
epacadostat combin keytruda metastat
melanoma fail combin unabl
improv progression-fre surviv keytruda alon
also unlik improv overal surviv hazard ratio
trend toward benefit compani
halt studi
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
valuat growth profit feb
increas fair valu estim per share
reflect time valu money favor
updat estim cost equiti
promis epacadostat
valuat mainli driven jakafi franchis
show encourag earli result combin
bristol yervoy melanoma current
evalu immunotherapi includ
bristol opdivo roch
tecentriq assum probabl approv
melanoma nsclc price
assumpt annual result peak
sale billion also optimist
compani partnership agenu
checkpoint
modul program direct gitr
howev yet attribut valu
model enter early-stag develop
jakafi continu strong perform mf pv
discontinu sanofi mf candid
well lacklust pivot
result gilead momelotinib cti pharma/baxalta
pacritinib believ jakafi near-term growth prospect
improv drug signific first-mov
advantag product could come
think approv jakafi polycythemia vera
potenti label expans essenti thrombocythemia
acut gvhd could lead peak sale billion
updat model reflect olumi approv
europ assum drug gain approv
base eli lilli resubmit
applic drug market
receiv royalti percentag sale
addit develop regulatori mileston
 approv translat royalti revenu near
billion toward end forecast period
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
administr myelofibrosi mf approv
polycythemia vera pv refractori patient drug
signific price power first-mov
advantag compet pipelin treatment jakafi
solid efficaci safeti profil patient popul
high unmet need allow compani set averag
annual price world-wide jakafi key patent
expir exclud potenti extens give
signific runway build franchis
expand et gvhd indic
pipelin competit thin recent year
forese signific near-term threat
gilead drug momelotinib cti biopharma/baxalta
drug pacritinib previous led competit
acquisit impact biomedicin earli
celgen reviv anoth competitor program fedratinib
continu believ jakafi set high bar next round
myelofibrosi
novel molecul
lilli inhibitor gandotinib -- expect
use patient toler jakafi
low level platelet fail jakafi therapi
near-term prospect promis view mani
early-stag competitor trial way includ
checkpoint inhibitor keytruda opdivo howev
believ earli candid signific
threat incyt jakafi franchis
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum program
reach market jakafi success expand
indic firm achiev greater oper
leverag result per share fair valu estim
bear-cas scenario model inhibitor
program enter market jakafi struggl
penetr mpn market oper cost
result signific financi burden base
case result fair valu drop per share
myeloprolif neoplasm mpn market includ
mf pv merit narrow econom moat rate firm
heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
robust pipelin mitig threat
futur jakafi sale compani sever early-
late-stag candid focus primarili oncolog
potenti becom lead next-gener
immuno-oncolog asset given like abil enhanc
efficaci checkpoint inhibitor incyt
incb inhibitor incb provid
addit shot net
immuno-oncolog target posit well
epacadostat combin keytruda opdivo
reveal impress efficaci hard-to-treat cancer
compani also sever earlier-stag candid
focus primarili oncolog autoimmun indic
recent partner checkpoint
modul program direct gitr
opportun remain rel unproven
incyt healthi pipelin give firm margin error
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin particular
believ incyt ido inhibitor epacadostat larg
potenti grow immuno-oncolog market
think jakafi carv strong defens
market posit addit label expans
pv drug achiev blockbust statu label
expans acut chronic graft-versus-host-diseas
et could boost futur jakafi sale olumi also
look promis rheumatoid arthriti market despit
steep competit given oral dose efficaci profil
drug receiv modest setback fda
dose concern complet respons letter earli
believ olumi eventu gain approv
 market due high efficaci approv
abbvi phase competitor upadacitinib look
efficaci olumi ra base top-lin result
trial key checkpoint
roch tecentriq
compani procur candid
advanc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
jakafi first fda-approv
treatment rare blood disord known
myelofibrosi give strong price power
oxeljanz delay european entri astrazeneca
abandon fostamatinib open door
baricitinib lead oral treatment
rheumatoid arthriti near term
select inhibitor program lead
market upend monopoli
ido inhibitor could fail show superior
efficaci ctla combin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end nearli billion cash
market secur limit debt balanc
sheet howev like biotechnolog compani incyt
histor oper loss high cost
clinic trial research loss
financ larg offer equiti debt
secur collabor research develop fund
arrang develop mileston partner
despit heavi spend expect firm
reach sustain profit near term especi
jakafi sale intern royalti off-set
high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent furthermor
baricitinib demonstr attract profil
conveni oral formul ra market highli
competit demonstr launch pfizer
xeljanz disappoint even though
first oral product market
upadacitinib demonstr clean safeti profil
drug could give olumi run money
market olumi yet approv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
respons research
develop cost entitl substanti royalti
mileston payment although execut
 commerci jakafi well without previou
experi view think would
difficult go alon competit rheumatoid arthriti
repres date owner name posit common share held report holder issuer
govern pension fund norway global
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
epacadostat failur blow merck
merck announc phase
studi epacadostat combin
keytruda metastat melanoma fail
combin unabl improv progression-fre surviv
keytruda alon unlik improv overal surviv
well hazard ratio trend toward
benefit compani halt studi expect
signific impact fair valu estim
weve previous point epacadostat
key driver compani valuat impact merck
mute compani alreadi establish
leader immuno-oncolog keytruda monotherapi
process launch gather data
combin keytruda variou regimen
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
fve catalyst horizon feb
follow incyt fourth-quart result increas
fair valu estim per share reflect
time valu money updat estim cost
equiti revenu compani jakafi franchis
market jakavi outsid match
thank pipelin progress off-set higher
research develop cost believ incyt jak
inhibitor program includ jakafi next-gener
regimen strong efficaci first-in-class advantag
rare blood disord market uncertainti lead
pivot read-out incyt ido inhibitor drug combin
merck keytruda unfairli weigh compani
share view
total fourth-quart revenu grew year year
driven year-over-year growth jakafi sale
myelofibrosi patient continu major
contributor robust jakafi adopt continu uptak
polycythemia vera patient also tend stay
drug longer provid strong tailwind sequenti
basi jakafi sale roughli flat due announc
inventori stock third quarter despit news
celgen reviv competitor jak program fedratinib
remain confid jak franchis set
high bar new entrant model jakafi sale
toward bottom end manag billion
guidanc higher previou think limit
headwind result updat regul close
donut hole expect impact first-quart growth
although strong new patient demand remain key driver
jakafi sale potenti label expans acut graft-
versus-host-diseas year-end pend posit result
first half year provid anoth near-term
catalyst firm
eye peel upcom pivot result incyt
ido program advanc melanoma expect
first half key driver valuat
trial compar ido/checkpoint inhibitor
combin checkpoint inhibitor monotherapi
believ trial need show compar efficaci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ctla drug regimen margin weaker efficaci coupl
superior safeti profil ctla combin could
also keep ido regimen competit posit
risk neg read-out ido combin
melanoma optimist expect
result believ investor cautiou use
melanoma conclus directli read
rest incyt ido inhibitor program either way
compani sever phase trial evalu
epacadostat combin checkpoint inhibitor
keytruda merck opdivo bristol imfinzi astrazeneca
across number oncolog indic
addit potenti jakafi label expans pivot
epacadostat result anticip two addit catalyst
year includ fda approv eli lilly-partn
rheumatoid arthriti drug baracitinib
incyt intern develop fgfr inhibitor cholangiocarcinoma
type ultra-rar cancer end year believ
bar competitor like upadacitinib
boast similar top-line efficaci increas research
develop forecast reflect grow late-
pipelin progress prompt jump
fve share under-valued
thank impress pipelin progress third
quarter increas fair valu estim incyt
per share strong perform
revis full-year sale guidanc
billion billion previous
adjust estim margin midpoint
guidanc boost partial off-set higher-than-
expect research develop cost
incyt recent announc licens
inhibitor candid million mani incyt
partner program progress rapidli
develop posit well futur
believ compani merit narrow econom moat
rate base strong uptak jakafi rare blood
disord high unmet need littl pipelin
competit horizon fair valu chang
share look slightli under-valued nov
jakafi third-quart sale grew year-over-year
driven continu ramp polycythemia vera patient
popul healthi growth patient sever
myelofibrosi rais estim slightli
account faster-than-expect penetr
drug limit impact valuat incyt
partner rheumatoid arthriti drug olumiantwhich
approv europ japan expect
reach follow complet respons
letteri slow start believ oral option like
olumi add compel value-add patient current
encumb inject drug treatment label expans
jakafi steroid-refractori acut graft-versus-host-
diseas bodi reject donor transplant could
occur earli pend posit pivot result
addit expans essenti thrombocythemia would
boost forecast sale
incyt immuno-therapi portfolio led promis ido
inhibitor epacadostat continu attract flurri activ
larg pharma partner loath lose
next wave immuno-oncolog innov lead
pack merck combin trial evalu
inhibitor keytruda epacadostat
metastat
melanoma phase result expect first half
howev drug also progress
pivot test across legion indic combin
merck keytruda astrazeneca imfinzi
bristol opdivo roch
tecentriq given multitud program
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
enter pivot test increas cost estim
research develop effort next
mani larg pharma compani
early-stag in-hous ido inhibitor could vie
epacadostat lead long term optimist
pipelin strategi focus doublet tripl
regimen compani recent licens
candid low expect in-
hous candid monotherapi given
domin current incumb think move
ensur match slew novel early-stag drug
target gitr arginas inhibitor
larg pharma partner ever pull back
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
